OncologyINDEEDNCT06350968
Implementation of Online Advance Care Planning Tool for (Hemato-)Oncological Patients Within the Cancer Network Concord
An observational study of Oncology and Advance Care Planning, run by Erasmus Medical Center at 1 site in Netherlands.
Trial summary
The aim of this mixed-methods study is to describe both the implementation process and outcomes of the online module Advance Care Plan for (hemato-)oncology patients within the oncology-network CONCORD. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Oncology, Advance Care Planning, Implementation
- How many people
- 30 participants
- Where
- 1 siteNetherlands
- Study dates
- 1 Oct 2023to 31 Dec 2026
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with all types of (advanced)cancer.
Who may be able to join
- Cancer
- Treated by hospital from the CONCORD-network
Who cannot join
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands1 site, 1 recruiting
- Recruiting
Joica Benschop
Rotterdam, 3023TB
Joica Benschop, MSc, +31622586583, j.benschop@erasmusmc.nl
Wendy Oldenmenger, PhD, +31651072608, w.h.oldenmenger@erasmusmc.nl
About this study
The aim of this mixed-methods study is to describe both the implementation process and outcomes of the online module Advance Care Plan for (hemato-)oncology patients within the oncology-network CONCORD.
The main question is: How is implementation and assurance of the advance care plan in daily care for (hemato-)oncological patients within CONCORD achieved, so that early integration of advance care planning in oncological care takes place and patient preferences are discussed?
Healthcare providers and patients are asked to use the module and share their experiences with it.
Read the detailed description
Design Implementation research with a mixed-method design. Population
The implementation of advance care planning should benefit the care of (hemato-)oncology patients aged 18 years and older during the palliative phase of their illness. The research focuses on:
- Oncology patients who have been treated in one or more hospitals from the oncology-network CONCORD after their death (quantitative research)
- Oncology patients treated with palliative intent in one or more hospitals from this network (interviews)
- Healthcare providers and implementation staff in the relevant hospitals and from the service area (interviews) Goal The aim of this project is to implement advance care planning in (hemato-)oncology patients treated in one of the hospitals within the oncology-network CONCORD , so that personal preferences and treatment agreements lead to an appropriate treatment plan. This is examined through the process of implementation and assurance of advance care planning in oncological care.
MAIN QUESTION: How is implementation and assurance of the online module advance care planning in daily care for (hemato-)oncological patients within the oncology-network CONCORD achieved, so that early integration of advance care planning in oncological care takes place and patient preferences are discussed? Method
Qualitative research:
Description of the initial situation and the context within each institution, but also of general practitioners and patients using the NASSS Framework. Interviews with project leader, project coordinators in each hospital, healthcare providers from 1st, 2nd and 3rd lines, patients and relatives at the start and end of the project (3-5 in each target group per hospital, taking into account the greatest possible degree of diversity in age, gender and background). At the end of the project, the interviews are repeated to gather information about the experiences and lessons learned and the experiences with facilitating and hindering factors. Each interview is transcribed and analyzed using NVivio or Atlas.ti, analysis programs for qualitative data.
Quantitative research:
EHR-research based on anonymized data using a dashboard. A dashboard is being built in each hospital to analyze data from (hemato-)oncological patients who have been treated in the relevant hospital and have died. The dashboard contains demographic and medical data, the use of the proactive care module and medical consumption in the last three months of their lives.
In each of the participating hospitals, the (hemato-)oncological patients who died in the last 3 months of 2022, 2023, 2024 and 2025 are selected and it will be examined to what extent the advance care plan has been completed and what kind of care the patients have received. A 'Health economic analysis' is carried out using the data from the dashboard. On the one hand, this involves the costs of implementing the advance care planning module used. In addition, the dashboard maps medical consumption in the last three months of life (e.g. ICU admissions, ER visits, clinical admissions, etc.). This is translated into the nationally determined costs for this. This is done both before and after implementation has been mapped out among people who have died, making it possible to gain insight into the difference in costs incurred.
- Conditions
- Oncology, Advance Care Planning, Implementation
- Keywords
- Advance Care Planning, Oncology
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Implementation outcome
Fidelity to the tailored implementation of the ACP-tool
Measured: 3 years
Secondary outcomes (2)
Intervention outcome
Healthcare use of patients with cancer in last phase of life (number of hospital admissions, ICU admissions, medication use, etc.)
Measured: 3 years
Implementation outcome
Number of filled-in ACP-tools in EHR
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2024
- Study start1 Oct 2023
- Primary completion30 Jun 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for OncologyStudies of the same condition, open and under way.
- More trials run by Erasmus Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Erasmus Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Maasstad Hospital, Spijkenisse Medical Center, Franciscus &Vlietland, IJsselland Hospital, Ikazia Hospital, Rotterdam, Van Weel-Bethesda hospital, Albert Schweitzer Hospital, Beatrix hospital
- Responsible party
- Principal investigator, Wendy Oldenmenger, RN PhD, Erasmus Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06350968
- Sponsor's protocol ID
- MEC-2023-0151
- Other IDs
- 10200012110003
- Acronym
- INDEED
- Status last verified
- Apr 2024
- First submitted
- 6 Dec 2023
- Last updated
- 8 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Benschop JAM, Korfage IJ, van der Heide A, van der Padt-Pruijsten A, van der Rijt CCD, Oldenmenger WH. Facilitating advance care planning in oncology: study protocol for the evaluation of a tailored implementation of an advance care planning tool (the INDEED study). BMC Palliat Care. 2026 Aug 14;25(1):323. doi: 10.1186/s12904-026-02285-9.
PubMed 42920159
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation of Online Advance Care Planning Tool for (Hemato-)Oncological Patients Within the Cancer Network Concord
- ClinicalTrials.gov ID
- NCT06350968
- Acronym / sponsor ID
- INDEED / MEC-2023-0151
- Conditions
- Oncology, Advance Care Planning, Implementation
- Keywords
- Advance Care Planning, Oncology
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Erasmus Medical CenterUniversity, hospital or other
- Collaborators
- Maasstad Hospital, Spijkenisse Medical Center, Franciscus &Vlietland, IJsselland Hospital, Ikazia Hospital, Rotterdam, Van Weel-Bethesda hospital, Albert Schweitzer Hospital, Beatrix hospital
- Study start
- 1 Oct 2023 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 8 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this mixed-methods study is to describe both the implementation process and outcomes of the online module Advance Care Plan for (hemato-)oncology patients within the oncology-network CONCORD.
The main question is: How is implementation and assurance of the advance care plan in daily care for (hemato-)oncological patients within CONCORD achieved, so that early integration of advance care planning in oncological care takes place and patient preferences are discussed?
Healthcare providers and patients are asked to use the module and share their experiences with it.
Detailed description
Design Implementation research with a mixed-method design. Population
The implementation of advance care planning should benefit the care of (hemato-)oncology patients aged 18 years and older during the palliative phase of their illness. The research focuses on:
- Oncology patients who have been treated in one or more hospitals from the oncology-network CONCORD after their death (quantitative research)
- Oncology patients treated with palliative intent in one or more hospitals from this network (interviews)
- Healthcare providers and implementation staff in the relevant hospitals and from the service area (interviews) Goal The aim of this project is to implement advance care planning in (hemato-)oncology patients treated in one of the hospitals within the oncology-network CONCORD , so that personal preferences and treatment agreements lead to an appropriate treatment plan. This is examined through the process of implementation and assurance of advance care planning in oncological care.
MAIN QUESTION: How is implementation and assurance of the online module advance care planning in daily care for (hemato-)oncological patients within the oncology-network CONCORD achieved, so that early integration of advance care planning in oncological care takes place and patient preferences are discussed? Method
Qualitative research:
Description of the initial situation and the context within each institution, but also of general practitioners and patients using the NASSS Framework. Interviews with project leader, project coordinators in each hospital, healthcare providers from 1st, 2nd and 3rd lines, patients and relatives at the start and end of the project (3-5 in each target group per hospital, taking into account the greatest possible degree of diversity in age, gender and background). At the end of the project, the interviews are repeated to gather information about the experiences and lessons learned and the experiences with facilitating and hindering factors. Each interview is transcribed and analyzed using NVivio or Atlas.ti, analysis programs for qualitative data.
Quantitative research:
EHR-research based on anonymized data using a dashboard. A dashboard is being built in each hospital to analyze data from (hemato-)oncological patients who have been treated in the relevant hospital and have died. The dashboard contains demographic and medical data, the use of the proactive care module and medical consumption in the last three months of their lives.
In each of the participating hospitals, the (hemato-)oncological patients who died in the last 3 months of 2022, 2023, 2024 and 2025 are selected and it will be examined to what extent the advance care plan has been completed and what kind of care the patients have received. A 'Health economic analysis' is carried out using the data from the dashboard. On the one hand, this involves the costs of implementing the advance care planning module used. In addition, the dashboard maps medical consumption in the last three months of life (e.g. ICU admissions, ER visits, clinical admissions, etc.). This is translated into the nationally determined costs for this. This is done both before and after implementation has been mapped out among people who have died, making it possible to gain insight into the difference in costs incurred.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with all types of (advanced)cancer.
Key inclusion criteria (2 listed)
- Cancer
- Treated by hospital from the CONCORD-network
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Implementation outcome
Time frame: 3 years
Fidelity to the tailored implementation of the ACP-tool
2 secondary outcomes
Intervention outcome
Time frame: 3 years
Implementation outcome
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2024.
- Derived from this study: PubMed 42920159Benschop JAM, Korfage IJ, van der Heide A, van der Padt-Pruijsten A, van der Rijt CCD, Oldenmenger WH. Facilitating advance care planning in oncology: study protocol for the evaluation of a tailored implementation of an advance care planning tool (the INDEED study). BMC Palliat Care. 2026 Aug 14;25(1):323. doi: 10.1186/s12904-026-02285-9.
Related trials for Oncology
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Oncology and Advance Care Planning, run by Erasmus Medical Center at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joica A.M. Benschop, MSc (+31622586583, j.benschop@erasmusmc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Implementation outcome (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06350968, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2024.